Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

SK Life Science

Status and phase

Enrolling

Phase 4

Conditions

Focal Onset Seizure

Treatments

Drug: Cenobamate

Study type

Interventional

Funder types

Industry

Identifiers

NCT06453213

YKP3089C049

Details and patient eligibility

About

Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagnosed or recurrent POS/focal onset epilepsy.

Full description

This is an uncontrolled, single-arm, open-label, Phase IV study conducted at approximately 40 sites in the US. It will consist of the following Periods:

Pretreatment Period (up to 21 days)
100 mg/day Treatment Period (6-week Titration Phase, 26-week Maintenance Phase)
200 mg/day Treatment Period (2-week Titration Phase, 26-week Maintenance Phase)
26-week Optional Extension Period
Follow Up Period (4 weeks)

Pretreatment Period At the screening visit (Visit 1) the investigator will obtain informed consent and assess the subject for their eligibility to participate in the study. The investigator will review any available hematology, chemistry blood tests, and ECGs. Vital signs and routine physical and neurological exam will be performed.

100 mg/day Treatment Period Subjects who complete screening and meet the inclusion/exclusion criteria begin the 32-week Treatment Period which includes a 6-week Titration Phase and a 26-week Maintenance Phase. During the Titration Phase subjects will be treated with cenobamate 12.5 mg/day for two weeks, 25 mg/day for two weeks and 50 mg/day for two weeks. Subjects tolerating cenobamate at the end of the Titration Phase will continue treatment with 100 mg/day in the Maintenance Phase for 26 weeks. At the end of the Maintenance Phase, the subject will have the option of continuing on in a 26-week Extension Period or discontinuing cenobamate. Subjects who experience a seizure during the 100 mg/day Maintenance Phase (with or without rescue medication use) will transition to the 200 mg/day Treatment Period.

200 mg/day Treatment Period: The 200 mg/day Treatment Period consists of a 2-week Titration Phase and a 26-week Maintenance Phase. During the 2-week Titration Phase, subjects will receive cenobamate 150 mg/day before entering the 26-week 200 mg/day Maintenance Phase. At the end of the Maintenance Phase, the subject will have the option of continuing on in a 26-week Extension Period or discontinuing cenobamate. If the subject experiences a seizure at 200 mg/day during the Maintenance Phase, then they will be discontinued from the study.

Optional Extension Period:

An Optional Extension Period will last 26 weeks. During the Optional Extension Period, Visits will occur at 13th week (Day 315/287a, Visit 8/8a) and 26th week (Day 406/378a, Visit 9/9a) to record vital signs and identify adverse events and occurrence of a seizure using a seizure diary. If a seizure occurs during the Optional Extension Period, the subject will be discontinued from the study.

Follow-up Period:

If a subject prematurely discontinues from the study, is not continuing into the Optional Extension Period or completes the last visit in the Optional Extension Period, cenobamate will be titrated down by 50% for two weeks and then discontinued. A follow-up visit should occur two weeks after the date of cenobamate discontinuation.

Enrollment

90 estimated patients

Sex

All

Ages

18 to 74 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Be considered reliable and willing to be available for the study period and are able to record seizures and report adverse events (AEs) himself/herself or have a caregiver who can record seizures and report AEs for them.
Male or female subjects 18-74 years of age with a diagnosis of partial-onset seizures (POS) according to the 2017 ILAE Classification of Epileptic Seizures. Diagnosis will be established by clinical history and an electroencephalogram (EEG) consistent with POS. Subjects with a normal EEG could be included provided they met the other diagnostic criteria according to clinical history.
Subjects who are newly diagnosed or have recurrent epilepsy and have experienced at least 2 unprovoked seizures separated by a minimum of 24 hours in the 1 year prior to Day 1 of the Treatment Period, of which, at least 1 unprovoked seizure (but below 20 seizures) occurred in the 12 weeks prior to Day 1 of the Treatment Period. Subjects with only 1 unprovoked seizure within the 12 weeks prior to Day 1 of the Treatment Period can be included if information is available to indicate that risk for a second seizure exceeds that which is usually considered to be epilepsy (about 60%). In the absence of clear information about recurrence risk, or even knowledge of such information, the default definition of epilepsy originates at the second unprovoked seizure. Subjects who are newly diagnosed and have been prescribed low dose of 1 ASM for ≤4 weeks can be included if the other ASM can be safely down-titrated/discontinued per Investigator discretion within 6 weeks of 1st dose of cenobamate. For subjects with recurrent epilepsy, they must have relapsed at least 2 years after the end of the last ASM treatment but can have been prescribed a low dose of 1 ASM for ≤4 weeks if the other ASM can be safely down-titrated/discontinued per Investigator discretion within 6 weeks of 1st dose of cenobamate.
Female subjects are either not of childbearing potential, defined as premenarchal, postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), if of childbearing potential, must comply with an acceptable method of birth control during the study, for at least 4 weeks prior to study entry and for 2 weeks after last dose of study drug.
Subject and/or caregiver(s)/legal representative must be willing and able to give informed assent/consent for participation in the study.
Subject and their caregiver must be willing and able (in the investigator's opinion) to comply with all study requirements.

Exclusion criteria

Subjects who have only simple partial-onset seizures (focal aware seizures) without motor signs.
Subjects who have seizure clusters where individual seizures cannot be counted.
Subjects who present with or have a history of Lennox-Gastaut syndrome.
Subjects who have a history of status epilepticus that required hospitalization within 1 year prior to Day 1 of the Treatment Period.
Subjects who have a history of psychogenic non-epileptic seizures within 2 years prior to Day 1 of the Treatment Period.
Subjects who have a history of active suicidal ideation within the last 6 months or suicide attempt within 2 years prior to Day 1 of Treatment Period.
Evidence of clinically significant disease (eg, cardiac, respiratory, gastrointestinal, psychiatric, other neurological) that in the opinion of the investigator(s) could affect the subject's safety or interfere with the study assessments.
History of Familial Short QT syndrome or prior subject diagnosis of Short QT syndrome.
Evidence of clinically significant active renal or hepatic disease.
Subjects taking a strong CYP3A inducer such as phenytoin, phenobarbital, carbamazepine, or rifampin within 12 weeks prior to the Pretreatment Period unless emergency care was needed due to the subject experiencing status epilepticus, uncontrolled seizures, or clusters of seizures.
Subjects who are taking more than one of the following centrally acting drugs: antipsychotic, antidepressant, or anxiolytic. The dose should be stable for the 12 weeks prior to the Pretreatment Period.
Subjects who have a history of any type of surgery for brain or central nervous system within 1 year prior to the Pretreatment Period.
Subjects who have a history of receiving any ASM (including ASM used as rescue treatment) for more than 4 weeks in total within 2 years prior to Day 1 of the Treatment Period.
Subjects who have used intermittent rescue medicine on 2 or more occasions within 4 weeks before the Pretreatment Period (1 to 2 doses over a 24-hour period considered one-time rescue).
Subjects who have a history of receiving any ASM polytherapy (> 2 ASMs) during a previous episode of epilepsy.
Previous exposure to cenobamate or sensitivity/allergy to components of the oral tablets.
Subjects who have a history of drug or alcohol dependency or abuse within the last 2 years before the Pretreatment Period.
Subjects who have had multiple drug allergies or a severe drug reaction, including dermatological (eg, DRESS syndrome, Stevens-Johnson syndrome), hematological, or organ toxicity reactions.
Females who are breastfeeding or pregnant or planning to get pregnant in the Pretreatment Period or during the conduct of the study.
Subjects who have participated in a study involving administration of an investigational drug or device within 4 weeks before Visit 1, or within approximately 5 half-lives of the previous investigational compound, whichever is longer.
Subjects with dementia.
Subjects who have seizures due to a progressive CNS condition.